Syndax Pharmaceuticals

Waltham, MA

Syndax is an oncology-focused biopharmaceutical company that is developing novel therapies in optimized, mechanistically driven combination regimens. The company is currently in multiple Phase 2a trials with its histone deacetylase inhibitor (HDACi) for breast cancer, lung cancer, and Hodgkin’s Lymphoma.